Product Approval (First‐in‐class treatment ) - Shilpa Medicare Ltd

Code BSE: 530549 NSE:

Shilpa Medicare Limited announces the approval of its, Nor Ursodeoxycholic Acid (NorUDCA) tablets 500 mg, by the Central Drugs Standard Control Organization (CDSCO), marking a major milestone in innovative NAFLD therapy in India. The approval reinforces Shilpa Medicare’s commitment to addressing unmet medical needs in hepatology through innovation and evidence‐based solutions. This approval will allow Shilpa to become the first company in the World to launch this novel product in any part of the World for NAFLD. NorUDCA is the first‐in‐class treatment for Non‐alcoholic Fatty Liver Disease (NAFLD) in India, addressing a significant unmet medical need.